不同HBV DNA检测方法对PEG-IFNɑ-2b治疗HBeAg阳性慢性乙型肝炎疗效判断的影响

郭春霞; 李嘉; 徐曾丽; 郭洁; 翟璐; 韩旭

doi:10.3969/j.issn.1001-5256.2017.04.013

不同HBV DNA检测方法对PEG-IFNɑ-2b治疗HBeAg阳性慢性乙型肝炎疗效判断的影响

DOI: 10.3969/j.issn.1001-5256.2017.04.013

1. 天津医科大学研究生院
2. 天津市第二人民医院肝病1科

基金项目:

天津市卫生局科技基金重点攻关项目(13KG126)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 309
- HTML全文浏览量: 42
- PDF下载量: 52
- 被引次数: 0
出版历程
- 出版日期: 2017-04-20

Impact of HBV DNA detection methods on evaluating the clinical effect of PEG-IFNɑ-2b in treatment of HBeAg-positive chronic hepatitis B: a comparative analysis

Gradual School of Tianjin Medical University

Research funding:

摘要

摘要:
目的在PEG-IFNα-2b治疗HBeAg阳性慢性乙型肝炎（CHB）过程中,探讨应用不同HBV DNA检测方法对疗效判断的影响。方法选取2014年9月-2016年1月天津市第二人民医院收治的CHB患者,应用PEG-IFNα-2b治疗24周内,HBV DNA低敏方法检测（最低检测下限500 IU/ml）首次阴转,且36周内低敏检测持续阴性的HBeAg阳性CHB患者83例。36周内采用高敏方法检测（最低检测下限20 IU/ml）持续阴性的患者（阴性组）33例,持续阳性的患者（阳性组）50例。对比2组在12、24和36周时HBeAg、HBsAg下降水平以及HBeAg血清学转换率。正态分布的计量资料2组间比较采用成组t检验;非正态分布的计量资料2组间比较采用Mann-Whitney U检验,计数资料2组间比较采用χ2检验。结果在HBV DNA低敏检测阴性后的12、24和36周,阴性组HBeAg下降值均明显优于阳性组,差异均有统计学意义[0.32（0.160.92）log10COI vs 0.14（0.010...
- 肝炎,乙型,慢性 /
- 肝炎病毒,乙型 /
- 干扰素α-2b /
- 治疗结果
Abstract:
Objective To investigate the impact of different HBV DNA detection methods on evaluating the clinical effect of PEG-IFNα-2b in the treatment of HBeAg-positive chronic hepatitis B (CHB) .Methods A total of 83 CHB patients who were admitted to Tianjin Second People's Hospital from September 2014 to January 2016 and treated with PEG-IFNa-2b for less than 24 weeks with clearance for the first time detected by HBV DNA low-sensitivity method (the lower limit of detection was 500 IU/ml) and negative results within 36 weeks obtained by low-sensitivity detection.Among these patients, 33 patients with negative results within 36 weeks obtained by high-sensitivity detection (the lower limit of detection was 20 IU/ml) were enrolled in negative group, and 50 with positive results were enrolled in positive group.The reductions in HBeAg and HBsAg and HBeAg seroconversion rate at 12, 24, and 36 weeks were compared between the two groups.The independent-samples t test was used for comparison of normally distributed continuous data between groups, the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between groups, and the chi-square test was used for comparison of categorical data between groups.Results At 12, 24, and 36 weeks after negative results were obtained by HBV DNA low-sensitivity detection, the negative group had a significant reduction in HBeAg than the positive group[12 weeks:0.32 (0.16-0.92) log10 COI vs 0.14 (0.01-0.30) log10 COI, Z=-3.061, P =0.002;24 weeks:0.44 (0.19-1.15) log10 COI vs 0.16 (0.04-0.35) log10 COI, Z=-3.043, P =0.002;36 weeka:0.51 (0.36-1.21) log10 COI vs 0.24 (0.10-0.46) log10 COI, Z=-3.880, P< 0.001].At 12 weeka after negative reaulta were obtained by HBV DNA low-aenaitivity detection, there waa no aignificant difference in the reduction in HBaAg (P-0.067) , while at 24 and 36 weeka, the negative group had a aignificant reduction in HBaAg than the poaitive group[24 weeka:0.13 (-0.02-0.33) log10 IU/ml vs 0.08 (-0.02-0.16) log10 IU/ml, Z =-2.207, P =0.021;36 weeka:0.16 (0.03-0.47) log10 IU/ml va 0.03 (-0.08-0.20) log10 IU/ml, Z =-2.363, P =0.018].At 12 weeka after negative reaulta were obtained by HBV DNA low-aenaitivity detection, there waa no aignificant difference in the HBeAg aeroconveraion rate between the negative group and the poaitive group (30.30%va 16.00%, P = 0.174) , while at 24 and 36 weeka, there were aignificant differencea between the two groupa (36.36%val6.00%and39.39%val8.00%, x2=4.507 and 4.671, P =0.040 and 0.042) .Conclusion In the treatment of HBeAg-poaitive CHB uaing PEG-IFN, high-aenaitivity detection methoda ahould be uaed to accurately evaluate the effect of antiviral therapy.
- hepatitis B, chronic /
- hepatitis B virus /
- interferon alfa-2b /
- treatment outcome

HTML全文

参考文献(11)

[1] KAO JH.Diagnosis of hepatitis B virus infection through serological and virological markers[J].Expert Rev Gastroenterol Hepatol, 2008, 2 (4) :553-562.

[2]POST A, NAGENDM S.Reactivation of hepatitis B pathogenesis and clinical implications[J].Curt Infect Dis Rep, 2009, 11 (2) :113-119.

[3]LIU S, LI Y, WEI W, et al.Design, synthesis, molecular docking studies and anti-HBV activity of phenylpropanoid derivatives[J].Chem Biol Interact, 2016, 251:1-9.

[4] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment of chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝脏病杂志, 2015, 31 (12) :1941-1960.

[5]PAN Y, WANG LN, SONG ZX, et al.Comparison of effects of entecavir and interferon therapy for HBe Ag-positive chronic hepatitis B[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (4) :392-395. (in Chinese) 潘玉, 王莉娜, 宋正霞, 等.恩替卡韦与干扰素治疗HBe Ag阳性慢性乙型肝炎的疗效[J/CD].中华实验和临床感染病杂志:电子版, 2016, 10 (4) :392-395.

[6]European Association for the Study of Liver Disease.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[7]LANG T, LO C, SKINNER N, et al.The hepatitis B e antigen (HBe Ag) targets and suppresses activation of the toll-like receptor signaling pathway[J].J Hepatol, 2011, 55 (4) :762-769.

[8] ISOGAWA M, ROBEK MD, FURUICHI Y, et al.Toll-like receptor signaling inhibits hepatitis B virus replication in vivo[J].J Virol, 2005, 79 (11) :7269-7272.

[9]MILICH D, LIANG TJ.Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection[J].Hepatology, 2003, 38 (5) :1075-1086.

[10]ZHANG HY, ZHOU P, GONG ZJ.Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B[J].J Clin Hepatol, 2016, 32 (5) :977-980. (in Chinese) 张海月, 周培, 龚作炯.HBs Ag定量检测对聚乙二醇干扰素治疗慢性乙型肝炎效果的预测价值[J].临床肝胆病杂志, 2016, 32 (5) :977-980.

[11]TJWA ET, van OORD GW, HEGMANS JP, et al.Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B[J].J Hepatol, 2011, 54 (2) :209-218.

施引文献

资源附件(0)

访问统计